Marksons Pharma PAT slips to Rs 46.28 in Q2FY22
Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021
Marksans Pharma has reported consolidated financial results for the period ended September 30, 2021
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
Subscribe To Our Newsletter & Stay Updated